Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (MELROSE)

randomized phase 3 study clearly demonstrated the superiority of osimertinib compared with erlotinib or gefitinib in EGFR mutated nonpretreated NSCLC (median PFS of 18.9 months versus 10.2 months).

erlotinib
tyrosine
kinase inhibitor
lung adenocarcinoma
gefitinib
  • 6 views
  • 08 Feb, 2022
  • 4 locations
A Phase I Dose Escalation Study for Patients With Recurrent Malignant Gliomas

This is a clinical trial (a type of research study). Clinical trials include only patients who choose to take part. You are being asked to take part in this study because you have a brain tumor that continued to grow despite prior therapy. Currently, there is no known effective treatment …

  • 7 views
  • 07 Nov, 2020
  • 1 location
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

The purpose of this study is studying icotinib following chemotherapy to see how well it works compared to chemotherapy in treating patients with resected stage IIA-IIIA NSCLC harboring EGFR mutation.

EGFR
  • 0 views
  • 22 Jan, 2021
  • 1 location
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

This single-arm, open, multicenter clinical study is going to evaluate the efficacy and safety of combination therapy with ectiecinib, pemetrexed and platinum in patients with metastatic non-squamous non-small cell lung cancer with EGFR mutations who did not progress after pemetrexed in combination with platinum-based chemotherapy.

aptt
platinum-based chemotherapy
EGFR
inulin clearance
metastasis
  • 0 views
  • 10 Feb, 2022
  • 1 location
Icotinib for Completed Resected IB NSCLC With EGFR Mutation

This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.

kidney function test
EGFR
icotinib
  • 7 views
  • 13 Aug, 2021
  • 1 location
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical …

  • 0 views
  • 13 May, 2021
  • 20 locations
Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

This is an open-label, single-intervention, multicenter clinical trial in patients with non-small cell lung cancer with asymptomatic or mildly symptomatic brain metastases after failure of EGFR TKI treatment. The objective of this study is as follows. Primary objective : intracranial objective response rate (iORR) with RECIST 1.1 Secondary objectives : …

lung cancer
afatinib
brain metastases
cancer
EGFR
  • 0 views
  • 06 May, 2022
  • 5 locations
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study (SELECT-2)

This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

erlotinib
adenocarcinoma
lung adenocarcinoma
cancer chemotherapy
gefitinib
  • 0 views
  • 12 Mar, 2022
  • 5 locations
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE)

Study Objectives are: To assess the safety of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after concomitant osimertinib and irradiation of tumor sites. To assess the efficacy of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive …

  • 0 views
  • 06 Jun, 2022
  • 1 location
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

STEREO is single-arm phase II study, which aims to evaluate the safety and efficacy of osimertinib combined with early locally ablative radiotherapy of all cancer sites in patients with synchronous oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC. Eradication of all macroscopic …

  • 0 views
  • 18 Apr, 2022